ORMP - Oramed Pharmaceuticals Inc. Total Debt to Capital

Oramed Pharmaceuticals (ORMP) maintains an excess liquidity reserve, enabling the advancement of scientific research without incurring debt. The price action vector available for analysis on GURU.Markets shows that the metric stands at 0.00, while business prospects depend on regulatory verdicts and partnerships with industry behemoths. Oramed Pharmaceuticals (ORMP) is developing patent-protected methods for oral drug delivery, including insulin, effectively blocking attempts to copy its technologies.

This metric is calculated as the ratio of total liabilities to equity, determining the business's degree of dependence on borrowed funds relative to owner resources. The low debt load reflected in the debt-to-equity ratio correlates with the Oramed Pharmaceuticals (ORMP) model of outsourcing research and maintaining a lean staff, which minimizes the company's operating expenses and financial risks.